Samsung Bioepis Co., Ltd.

This phase 3 trial tests whether SB27, a proposed biosimilar to the cancer drug Keytruda, works as well as the original in people with advanced non-squamous non-small cell lung cancer. About 555 participants will receive either SB27 or Keytruda plus chemotherapy every 3 weeks. Th…

This trial compares a biosimilar drug (SB27) to the standard cancer immunotherapy Keytruda in 163 people with stage II-IIIA non-small cell lung cancer who have already had surgery and chemotherapy. The main goal is to see if the body processes SB27 the same way as Keytruda. If su…